Journal of Clinical & Experimental OncologyISSN: 2324-9110

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

DECONSTRUCTION – RECONSTRUCTION of the tumour


Oliver L

Universite de Nantes, France

: J Clin Exp Oncol

Abstract


Our group works on Glioblastoma Multiforme (GBM) tumours. In collaboration with neurosurgeons we obtain tumours from the tumorotheque, which are disassociated mechanically with the aim of recuperating all the cells present in the tumour. It is well known that the Glioblastoma consists of a heterogeneous cell population and our culture conditions allow for the proliferation and survival of all the cell types present in the original tumour. This first part would represent the deconstruction of the tumour and at present we have at our disposition a collection of 80 primary cultures of GBMs. Initial experiments have shown that in the present of “Cancer-associated Fibroblasts” or CAFs, tumour cells proliferate more and respond less to irradiation and temolozolamide (TMZ) (principal treatment for GBM). For the second part of our project namely the “reconstruction” we have developed a system of 3D-bioprinting, which would include adding a mixture of primary GBM cells and CAFs in a matrix of hydrogel and collagen that would represent our bioink. Using a 3D-bioprinter we would then reconstruct the tumour. The reconstructed tumour scaffolds should all be identical and contain similar cell numbers that are important in the analyses. Once tumour cell aggregates are visible in the scaffolds, these scaffolds would be used to determine the role of CAFs in the “protection – survival” of the tumour after chemo- (100 μM TMZ) and/or radiotherapy

Biography


L. Oliver completed her PhD at the University of Paris VII, France. Presenting working in the group of Dr Francois Vallette at “Centre of Research in Cancer-Immunology Nantes-Angers”. She has published over 80 articles in reputed journals.

E-mail: [email protected]

Track Your Manuscript

Media Partners

GET THE APP